The importance of early bedside echocardiography in children with scorpion envenomation
Biomarkers of prolonged exposure to microcystin-LR in mice
Toxicokinetics of Naja sputatrix (Javan spitting cobra) venom following intramuscular and intravenous administrations of the venom into rabbits
A novel method for preparing complete antigens of gonyautoxin 2,3 and their feature of immunogenicity
The pathological effects of Heminecrolysin, a dermonecrotic toxin from Hemiscorpius lepturus scorpion venom are mediated through its lysophospholipase D activity
The life history of a botulinum toxin molecule
The life history of a botulinum toxin molecule
Genetic diversity between and within botulinum neurotoxin serotypes
Identification, purification and characterization of botulinum neurotoxin type A subtype toxins
Binding receptors of botulinum neurotoxins
Botulinum neurotoxin–host interactions
Botulinum neurotoxins and the neuroexocytosis nanomachine
The structure of botulinum neurotoxin under its bio-shield
Neurobiological basis for the use of botulinum toxin in pain therapy
Effect of botulinum toxin on pain transduction and transmission
Botulinum toxin in headache disorders
Botulinum toxin in rare pain disorders
Re-targeting of botulinum neurotoxins
Blocking botulism – A journey into modules and modulators
Function of the translocation domain belt
Mode of substrate binding and cleavage
Molecular mechanism of calcium-triggered vesicle fusion
Towards a molecular understanding of botulinum neurotoxin persistence
Ganglioside binding of botulinum neurotoxin serotype D–South Africa
Comparative trials of botulinum toxin therapeutics
Advances in toxin therapy: Utilizing ultrasound guidance for botulinum toxin injections
Mechanisms of antibody neutralization of botulinum neurotoxins
Antigenicity of botulinum toxin drugs
The evolution of Clostridia
Central nervous system effects of botulinum neurotoxins
Retrograde transport of proteins in the central nervous system
Peripheral cholinergic specificity of botulinum type A neurotoxin
Mechanism of action of botulinum neurotoxin in hyperhidrosis
Botulinum toxin for detrusor overactivity
Use of botulinum neurotoxin to treat depression
Dose equivalence and potential systemic toxicity of botulinum neurotoxins
Counterfeit botulinum neurotoxin drugs
Non-A/non-B botulinum toxin for therapeutic use
Reducing animal consumption for the production of botulinum neurotoxin drugs
The registration process for botulinum neurotoxin drugs: The perspective of developing countries
The registration process for botulinum neurotoxin drugs: The perspective of the regulatory authorities
RimabotulinumtoxinB for preventive treatment of migraine headaches
Case report with sequential nerve conduction studies: A very old patient with atypical foodborne botulism type a with pupil sparing treated with botulinum antitoxin
Behavioral and electrophysiological studies of A2NTX and A1LL
Molecular dissection of the botulinum neurotoxin type G synaptotagmin binding site
Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5
Neuronal targeting, internalization and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A
Are standard doses of incobotulinumtoxinA, botulinum neurotoxin A free from complexing proteins, not detected by the human immune system?
The frontalis test versus research and commercial mouse protection antibody assays and exposure history in clinical resistance to botulinum toxin therapy in cervical dystonia
Sensitivity and persistence in BoNT-Treated embryonic stem cell-derived neurons
Novel and highly sensitive cell model for botulinum neurotoxin detection using human neurons from induced pluripotent stem cells
Treatment-induced change of cortical activation: fMRI evidence of the central effect of botulinum toxin A in idiopathic dystonia and post-stroke spasticity
Botulinum toxin type A in post-stroke spasticity: Clinical trials with functional measures
The dystonia coalition: Two years of progress
Simultaneous or sequential injection of botulinum neurotoxin A does not reduce the duration of paralysis by botulinum neurotoxin A in rat EDL muscle
Effect of growth factors on recovery from botulinum neurotoxin-induced paralysis
Location of the synaptosome binding regions on botulinum neurotoxin type B
Effects of botulinum toxin type A on digit abduction score and running wheel assays and assessment of diffusion using calcium-activated potassium channel expression
Molecular pharmacophores against BoNT/B
Zebrafish ( Danio rerio ) as a model to study the effects of botulinum neurotoxin type E and visceral toxicosis of catfish
Antibody protection of mice from botulinum neurotoxin serotype B intoxication
New SV2c construct for use in binding and detecting botulinum neurotoxin type A
In silico design and experimental screening of real-time PCR assays for the detection of Clostridium perfringens and Clostridium tetani toxin genes
Rapid detection of botulinum neurotoxin serotypes A and F activity in complex matrices
Salt-dependent dissociation of botulinum neurotoxin type A complexes
Monoclonal antibodies against botulinum neurotoxin serotype F
Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function
Botulinum toxin products contain different amounts of the 150 kD neurotoxin
Human monoclonal antibodies binding botulinum neurotoxin types C, D, and mosaic neurotoxins C-D and D-C
Levetiracetam, an SV2A ligand, does not prolong survival of mice intoxicated with botulinum toxins A or E
Establishment of an alternative potency test for botulinum neurotoxin type A using muscle action potential change in rats
Identification of fibroblast growth factor receptor 3 as a protein receptor for botulinum neurotoxin serotype A
Recovery after repeated BoNT/A administration in the rat gastrocnemius muscle
Quantification of botulinum neurotoxin in intoxicated neurons
Mouse compound muscle action potential assay – Suggestion of an alternative method to the LD50 potency test of botulinum toxin type A
Novel in vivo test shows low-dosage botulinum toxin-induced focal calf muscle paresis is independent of increased muscle activity in wild-type mice
Low-dosage tetanus neurotoxin induces focal, temporarily increased muscle tone in wild-type mice
Generation, expression and purification of monoclonal-antibody-specific engineered domains to support development of oligoclonal recombinant antitoxins against BoNT/B and BoNT/E
Is retrograde transport of botulinum neurotoxin type A involved in its analgesic effects on neuropathic pain?
Methods to produce, culture and evaluate embryonic stem-cell-derived neurons as a research tool for botulinum toxin and the black widow spider venom latrotoxin
Identification of the SV2-binding site of botulinum neurotoxin type E
Non-clinical safety evaluation of XOMA 3AB, a novel triple antibody drug product targeting botulinum toxin type A, in Sprague-Dawley rats
Development of a cell-based assay using primary granular cells and glutamate release: A parallel with the EzyBot endopeptidase assay
Enzymatic activity quantification of botulinum neurotoxins A and B in serum by mass spectrometry
Development of an in vitro assay for detecting botulinum neurotoxin type E with application to avian botulism in the Great Lakes
Double anchorage to the membrane and intact interchain disulfide bond are required for the low-pH-induced entry of tetanus and botulinum neurotoxins into neurons
Recovery and detection of botulinum toxin type A from drinking water
Simultaneous detection and differentiation of botulinum toxin serotypes A and B by internally-quenched fluorogenic peptides
The function of the HCN-domain of clostridial neurotoxins
Preliminary results of the AntiBotABE project: Identification of neutralizing scFvs antibodies against botulinum toxins A and B
Development of functional cell-based assays as replacement assays for botulinum toxins and antitoxins
In vivo functional actions of type A botulinum toxins
New FRET substrate for botulinum neurotoxin type A
A Strategy for rapid development and simplified production of therapeutic antitoxins tested on botulinum neurotoxin
An improved oral toxicity profile of a novel botulinum toxin type A formulation
Analysis of interaction of type B botulinum hemagglutinin with E-cadherin
Comparison of neutralizing abilities of human monoclonal antibodies binding different epitopes on botulinum neurotoxin A
Sensitive detection of botulinum neurotoxin type A using high-affinity polyclonal antibodies
Botulinum neurotoxin A inhibits acetylcholine exocytosis independent of SNAP-25 cleavage
Recombinant monoclonal-antibody-based antitoxins for treatment of types A, B, and E botulism
Botulinum toxins subtypes A1 and A2 were transported via different pathways to the contralateral side
Immunological difference between botulinum toxin subtypes A1 and A2 using polyclonal antibody
Design and enzymatic response of engineered botulinum neurotoxin B-insensitive VAMP-2 mutants
Development of an ELISA microarray platform for the sensitive and quantitative detection of botulinum neurotoxins
Use of multiple enzymes in sequential in-gel digestions improves sequence coverage of botulinum neurotoxins for confident subtyping by mass spectrometry
Effects of botulinum-neurotoxin-complexing proteins on lymphatic cells
Clostridium tetani clones identified by Multilocus Variable-Number Tandem-Repeat Analysis
Development of serotype-specific monoclonal antibodies against botulinum neurotoxins A, B and E, based on a trivalent immunization protocol and simultaneous differential robotic screen
Structural basis for the inhibition of botulinum neurotoxin serotype A by potent peptidomimetics
Communication calendar for botulinum toxin therapy of spasticity in an outpatient setting
RimabotulinumtoxinB in the treatment of refractory pain in fibromyalgia: A case series
Is there a role for rimabotulinumtoxinB In the treatment of medication-resistant low back pain?
Botulinum toxin type A as an adjunct treatment to radiation-induced trismus
Performance and mouse bioassay comparability of the BoCell™ A cell-based assay
Use of botulinum toxin type A injections to the levator ani and obturator internus muscles in cases of perineal pain associated with pelvic floor muscle overcontraction and myalgia
Stability of reconstituted botulinum toxin type A-containing products
OnabotulinumtoxinA for chronic migraine: PREEMPT trials establish a safe and effective dose and injection paradigm
Adult cervical dystonia patients first treated with onabotulinumtoxinA exhibit comparable onset and duration of effect, time between visits, dose usage and safety profiles when switched to incobotulinumtoxinA
Repeated incobotulinumtoxinA injections with flexible dosing intervals in blepharospasm
Design of ANCHOR-CD (AbobotulinumtoxinA Neurotoxin: Clinical and Healtheconomics Outcomes Registry-Cervical Dystonia)
Safety and immunogenicity study of rimabotulinumtoxinb in patients with cervical dystonia
Treatment of drooling in different neurological disorders with ultrasound-guided injections of botulinum neurotoxin type B into salivary glands
Electrophysiological correlates of cervical dystonia therapy with onabotulinum toxin type A
Phase 3 efficacy and safety study of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity
OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phase of the PREEMPT clinical program
An enzyme-linked immunosorbent assay for detection of botulinum toxin antibodies
The use of botulinum toxin in the treatment of male pattern baldness
Vascular targeting for botulinum toxin pain injections
Botulinum toxin A in the treatment of facial reflex sympathetic dystrophy: A case report
Goal category influence on the success of post-stroke spasticity treatment with botulinum toxin type A
Treating severe bruxism in patients with cerebral palsy with onabotulinumtoxinA
Clinical improvement in secondary non-responders to ona- or abobotulinumtoxinA when treated with incobotulinumtoxinA
Abobotulinumtoxin A dosing in cervical dystonia: An analysis of two large open-label extension studies
IncobotulinumtoxinA drug product demonstrates lower potency when compared to onabotulinumtoxinA drug product with concurrent lower light-chain activity and atypical substrate cleavage
Reconstituted onabotulinumtoxinA retains potency and safety under extended refrigerated storage
Goal attainment analysis in post-stroke spasticity treatment with botulinum toxin type A
Baseline characteristics and botulinum toxin type A dosing patterns for patients with movement disorders in a prospective observational cohort study: Mobility
Significant and sustained efficacy of incobotulinumtoxinA in upper limb spasticity
Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: A randomized, double-blinded, active controlled multicenter study
An international observational study to define in real-life practice response to botulinum toxin type A injection in subjects with idiopathic cervical dystonia
OnabotulinumtoxinA for treatment of refractory cancer pain
Electrophysiological study for assessment of botulinum toxin type A2 compared with type A1 in healthy volunteers
Botulinum toxin type A in hip adductor spasticity in primary progressive multiple sclerosis
Cervical Dystonia Patient Registry for Observation of onaBotulinumtoxinA Efficacy (CD PROBE): Interim results of physician- and patient-reported outcomes
What requirements are needed for optimal treatment of patients in a movement disorder clinic specialized in treating patients with dystonia?
Treating hand tremor in Parkinson disease with botulinum neurotoxin type A: A pilot study
The role of the obliquus capitis inferior muscle in dystonic torticaput
Safety and efficacy of topical botulinum toxin type A for the treatment of moderate to severe lateral canthal lines – A review of the U.S. Phase 2b experience
Botulinum toxin therapy in the presence of anticoagulation: Hematoma frequency
Diffusion properties of two botulinum toxin type A complexes–post-hoc analysis of data from a double-blind, randomized, dose-ranging study
Intraarticular botulinum toxin reduced joint pain in patients with painful total knee or shoulder arthroplasty
Repeated incobotulinumtoxinA injections with flexible dosing intervals in cervical dystonia
Usefulness of botulinum toxin A in complex regional pain syndrome
An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: A randomized controlled trial
Electroneurographic pilot study with healthy volunteers to determine the efficacy, safety and duration of action of TrapoX, a potency-optimised botulinum toxin type A-based mutant
Acknowledgement to Reviewers 2012